Cardiovascular disease (CVD) is responsible for up to 25% of premature deaths in the UK, 80% of which are preventable. We explore the role integrated care systems could play in scaling up the ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

Treating coronary artery disease patients with monotherapy using clopidogrel or ticagrelor was associated with lower rates of ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The Matthew J. Morahan III Health Assessment Center for Athletes has provided over 50,000 concussion and cardiac screenings ...